“Increased Adoption of Advanced Molecular Diagnostic Techniques”
- A major and rapidly accelerating trend in the global laboratory-developed tests (LDTs) market is the growing adoption of advanced molecular diagnostic techniques such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and liquid biopsy. These technologies are enabling high-precision diagnostics for a wide range of conditions, including cancer, infectious diseases, and genetic disorders
- For instance, the use of NGS-based LDTs allows for comprehensive genomic profiling of tumors, helping clinicians tailor targeted therapies and improve treatment outcomes. Similarly, PCR-based LDTs are extensively utilized for the rapid detection of pathogens such as SARS-CoV-2, supporting timely clinical decision-making during pandemics and outbreaks
- These advanced diagnostic platforms provide critical benefits, such as faster turnaround times, higher sensitivity, and the ability to detect low-abundance biomarkers. As a result, healthcare providers are increasingly relying on them for early diagnosis, disease monitoring, and personalized treatment planning
- The integration of such cutting-edge techniques into LDT workflows also facilitates multiplex testing—simultaneous detection of multiple targets from a single patient sample—enhancing laboratory efficiency and reducing costs
- Moreover, innovations in sample preparation, reagent development, and automation are further streamlining these diagnostic processes, enabling laboratories to scale testing capabilities and maintain high throughput
- Driven by the need for more accurate, efficient, and scalable diagnostic solutions, the demand for LDTs incorporating advanced molecular technologies is witnessing significant growth across clinical laboratories, academic research centers, and specialized diagnostic facilities globally
